검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD7 CAR T-cells |
Overview Company | iCell Gene Therapeutics |
Overview Modality | CGT |
Overview Target | Crohn Disease |
Overview Indication | T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | CD19 CAR T-cells produce high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.. BACKGROUND: Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7+ T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide, a process of self-cytotoxicity caused by the shared ex… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD7 CAR T-cells |
Overview Company | iCell Gene Therapeutics |
Overview Modality | CGT |
Overview Target | Crohn Disease |
Overview Indication | T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | CD19 CAR T-cells produce high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.. BACKGROUND: Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7+ T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide, a process of self-cytotoxicity caused by the shared ex… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교